Genomic characterization of acute leukemias

Medical Principles and Practice

Volumn 23, Issue 6, 2014, Pages 487-506

  Chiaretti, Sabina ^a   Gianfelici, Valentina ^a   Ceglie, Giulia ^a   Foà, Robin ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Acute leukemias; Genomic aberrations; Next generation sequencing

Indexed keywords

BCR ABL PROTEIN; MICRORNA; MOLECULAR MARKER; NOTCH1 RECEPTOR; PROTEIN P53;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; B LYMPHOCYTE; B LYMPHOCYTE ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER RECURRENCE; CHROMOSOME ABERRATION; CYTOGENETICS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC DISORDER; GENOMICS; HIGH RISK POPULATION; HUMAN; MEDICAL HISTORY; PERSONALIZED MEDICINE; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE DISEASE; ACUTE MYELOBLASTIC LEUKEMIA; AGE; COMPARATIVE GENOMIC HYBRIDIZATION; GENETICS; KARYOTYPING; LEUKEMIA; MUTATION; SEX DIFFERENCE;

ACUTE DISEASE; AGE FACTORS; COMPARATIVE GENOMIC HYBRIDIZATION; GENE EXPRESSION PROFILING; HUMANS; KARYOTYPING; LEUKEMIA; LEUKEMIA, MYELOID, ACUTE; MICRORNAS; MUTATION; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SEX FACTORS;

EID: 84911422625     PISSN: 10117571     EISSN: 14230151     Source Type: Journal    
DOI: 10.1159/000362793     Document Type: Review

References (215)

1. Inaba H, Greaves M, Mullighan CG: Acute lymphoblastic leukemia. Lancet 2013;381:1943-1955.
2. Nowell PC, Hungerford DA: A minute chromosome in human chronic granulocytic leukemia. Science 1960;132:1497-1499.
3. Sattler M, Griffin JD: Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol 2003;40:4-10.
4. Melo JV, Deininger MW: Biology of chronic myelogenous leukemia - signaling pathways of initiation and transformation. Hematol Oncol Clin North Am 2004;18:545-568, vii-viii.
5. Faderl S, Garcia-Manero G, Thomas DA, et al: Philadelphia chromosome-positive acute lymphoblastic leukemia - current concepts and future perspectives. Rev Clin Exp Hematol 2002;6:142-160.
6. Pane F, Frigeri F, Sindona M, et al: Neutrophilicchronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood 1996;88:2410-2414.
7. Chiaretti S, Vitale A, Cazzaniga G, et al: Clinicobiologic features of 5, 202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age-cohorts. Haematologica 2013;98:1702-1710.
8. Vignetti M, Fazi P, Cimino G, et al: Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. Blood 2007;109:3676-3678.
9. Ottmann O, Dombret H, Martinelli G, et al: Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 2007:110:2309-2315.
10. Schultz KR, Bowman WP, Aledo A, et al: Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a Children's Oncology Group study. J Clin Oncol 2009;27:5175-5181.
11. Ravandi F, Kebriaei P: Philadelphia chromosomepositive acute lymphoblastic leukemia. Hematol Oncol Clin North Am 2009;23:1043-1063.
12. Gruber F, Mustjoki S, Porkka K: Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia. Br J Haematol 2009;145:581-597.
13. Foà R, Vitale A, Vignetti M, et al; GIMEMA Acute Leukemia Working Party: Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2011;118:6521-6528.
14. Harrison CJ: Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia. Br J Haematol 2009;144:147-156.
15. Loh ML, Rubnitz JE: TEL/AML1-positive pediatric leukemia: prognostic significance and therapeutic approaches. Curr Opin Hematol 2002;9:345-352.
16. Speck NA, Gilliland DG: Core-binding factors in haematopoiesis and leukaemia. Nat Rev Cancer 2002;2:502-513.
17. Hiebert SW, Sun W, Davis JN, et al: The t (12; 21) translocation converts AML-1B from an activator to a repressor of transcription. Mol Cell Biol 1996;16:1349-1355.
18. Meyer C, Kowarz E, Hofmann J, et al: New insights to the MLL recombinome of acute leukemias. Leukemia 2009;23:1490-1499.
19. Meyer C, Hofmann J, Burmeister T, et al: The MLL recombinome of acute leukemias in 2013. Leukemia 2013;27:2165-2176.
20. Corral J, Lavenir I, Impey H, et al: An MIIAF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogenes. Cell 1996;85:853-861.
21. Dobson CL, Warren AJ, Pannell R, et al: The mll-AF9 gene fusion in mice controls myeloproliferation and specifies acute myeloid leukaemogenesis. EMBO J 1999;18:3564-3574.
22. Ayton PM, Cleary ML: Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev 2003;17:2298-2307.
23. Carroll AJ, Crist WM, Parmley RT, et al: Pre-B cell leukemia associated with chromosome translocation 1; 19. Blood 1984;63:721-724.
24. Hunger SP: Chromosomal translocations involving the E2A gene in acute lymphoblastic leukemia: clinical features and molecular pathogenesis. Blood 1996;87:1211-1224.
25. Aspland S, Bendall HH, Murre C: The role of E2A-PBX1 in leukemogenesis. Oncogene 2001;20:5708-5711.
26. Pui CH, Evans WE: Treatment of acute lymphoblastic leukemia. N Engl J Med 2006;354:166-1678.
27. Foa R, Vitale A, Mancini M, et al: E2A-PBX1 fusion in adult acute lymphoblastic leukaemia: biological and clinical features. Br J Haematol 2003;120:484-487.
28. Burmeister T, Gökbuget N, Schwartz S, et al: Clinical features and prognostic implications of TCF3-PBX1 and ETV6-RUNX1 in adult acute lymphoblastic leukemia. Haematologica 2010;95:241-246.
29. Golub TR, Slonim DK, Tamayo P, et al: Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999;286:531-537.
30. Yeoh EJ, Ross ME, Shurtleff SA, et al: Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002;1:133-143.
31. Ross ME, Zhou X, Song G, et al: Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood 2003;102:2951-2959.
32. Kohlmann A, Schoch C, Schnittger S, et al: Pediatric acute lymphoblastic leukemia (ALL) gene expression signatures classify an independent cohort of adult ALL patients. Leukemia 2004;18:63-71.
33. Chiaretti S, Li X, Gentleman R, et al: Gene expression profiles of B-lineage adult acute lymphocytic leukemia reveal genetic patterns that identify lineage derivation and distinct mechanisms of transformation. Clin Cancer Res 2005;11:7209-7219.
34. Haferlach T, Kohlmann A, Schnittger S, et al: Global approach to the diagnosis of leukemia using gene expression profiling. Blood 2005;106:1189-1198.
35. Irving JA, Bloodworth L, Bown NP, et al: Loss of heterozygosity in childhood acute lymphoblastic leukemia detected by genome-wide microarray single nucleotide polymorphism analysis. Cancer Res 2005;65:3053-3058.
36. Mullighan CG, Goorha S, Radtke I, et al: Genomewide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007;446:758-764.
37. Paulsson K, Cazier JB, Macdougall F, et al: Microdeletions are a general feature of adult and adolescent acute lymphoblastic leukemia: unexpected similarities with pediatric disease. Proc Natl Acad Sci USA 2008;105:6708-6713.
38. Kawamata N, Ogawa S, Zimmermann M, et al: Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray. Blood 2008;111:776-784.
39. Kuiper RP, Schoenmakers EF, van Reijmersdal SV, et al: High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression. Leukemia 2007;21:1258-1266.
40. Pui CH, Robison LL, Look AT: Acute lymphoblastic leukemia. Lancet 2008;371:1030-1043.
41. Georgopoulos K, Bigby M, Wang JH, et al: The Ikaros gene is required for the development of all lymphoid lineages. Cell 1994;79:143-156.
42. Tonnelle C, Bardin F, Maroc C, et al: Forced expression of the Ikaros 6 isoform in human placental blood CD34 (+) cells impairs their ability to differentiate toward the B-lymphoid lineage. Blood 2001;98:2673-2680.
43. Tonnelle C, Dijon M, Moreau T, et al: Stage specific over-expression of the dominant negative Ikaros 6 reveals distinct role of Ikaros throughout human B-cell differentiation. Mol Immunol 2009;46:1736-1743.
44. Trageser D, Iacobucci I, Nahar R, et al: Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function. J Exp Med 2009;206:1739-1753.
45. Collins-Underwood JR, Miller CB, Downing JR, et al: Ikzf1 haploinsufficiency contributes to the pathogenesis of BCR-ABL1 positive acute lymphoblastic leukemia (abstract 678). Blood 2009;114:283.
46. Mullighan CG, Miller CB, Radtke I, et al: BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008;453:110-114.
47. Iacobucci I, Storlazzi CT, Cilloni D, et al: Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). Blood 2009;114:2159-2167.
48. Martinelli G, Iacobucci I, Storlazzi CT, et al: IKZF1 (Ikaros) deletions in BCRABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J Clin Oncol 2009;27:5202-5207.
49. Mullighan CG, Su X, Zhang J, et al; Children's Oncology Group: Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009;360:470-480.
50. Kuiper RP, Waanders E, van der Velden VH, et al: IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Leukemia 2010;24:1258-1264.
51. Levin SD, Koelling RM, Friend SL, et al: Thymic stromal lymphopoietin: a cytokine that promotes the development of IgM+ B cells in vitro and signals via a novel mechanism. J Immunol 1999;162:677-683.
52. Brown VI, Hulitt J, Fish J, et al: Thymic stromalderived lymphopoietin induces proliferation of pre-B leukemia and antagonizes mTOR inhibitors, suggesting a role for interleukin-7Ralpha signaling. Cancer Res 2007;67:9963-9970.
53. Mullighan CG, Collins-Underwood JR, Phillips LA, et al: Rearrangement of CRLF2 in Bprogenitorand Down syndrome-associated acute lymphoblastic leukemia. Nat Genet 2009;41:1243-1246.
54. Hertzberg L, Vendramini E, Ganmore I, et al: Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood 2010;115:1006-1117.
55. Russell LJ, Capasso M, Vater I, et al: Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood 2009;114:2688-2698.
56. Cario G, Zimmermann M, Romey R, et al: Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. Blood 2010;115:5393-5397.
57. Harvey RC, Mullighan CG, Chen IM, et al: Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood 2010;115:5312-5321.
58. Yoda A, Yoda Y, Chiaretti S, et al: Functional screening identifies CRLF2 in precursor Bcell acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2010;107:252-257.
59. Den Boer ML, van Slegtenhorst M, De Menezes RX, et al: A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol 2009;10:125-134.
60. Harvey RC, Mullighan CG, Wang X, et al: Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood 2010;116:4874-4884.
61. Roberts KG, Morin RD, Zhang J, et al: Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 2012;22:153-166.
62. Robinson HM, Broadfield ZJ, Cheung KL, et al: Amplification of AML1 in acute lymphoblastic leukemia is associated with a poor outcome. Leukemia 2003;17:2249-2250.
63. Harewood L, Robinson H, Harris R, et al: Amplification of AML1 on a duplicated chromosome 21 in acute lymphoblastic leukemia: a study of 20 cases. Leukemia 2003;17:547-553.
64. Strefford JC, van Delft FW, Robinson HM, et al: Complex genomic alterations and gene expression in acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21. Proc Natl Acad Sci USA 2006;103:8167-8172.
65. Moorman AV, Richards SM, Robinson HM, et al; UK Medical Research Council (MRC)/National Cancer Research Institute (NCRI) Childhood Leukaemia Working Party (CLWP): Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21). Blood 2007;109:2327-2330.
66. Rand V, Parker H, Russell LJ, et al: Genomic characterization implicates iAMP21 as a likely primary genetic event in childhood B-cell precursor acute lymphoblastic leukemia. Blood 2011;117:6848-6855.
67. Holmfeldt L, Wei L, Diaz-Flores E, et al: The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 2013;45:242-252.
68. Hof J, Krentz S, van Schewick, et al: Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. J Clin Oncol 2011;29:3185-3193.
69. Krentz S, Hof J, Mendioroz A, et al: Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia. Leukemia 2013;27:295-304.
70. Chiaretti S, Brugnoletti F, Tavolaro S, et al: TP53 mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poor response to induction therapy. Haematologica 2013;98:e59-e61.
71. Aas T, Børresen AL, Geisler S, et al: Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996;2:811-814.
72. Poeta ML, Manola J, Goldwasser MA, et al: TP53 mutations and survival in squamouscell carcinoma of the head and neck. N Engl J Med 2007;357:2552-2561.
73. Fenaux P, Preudhomme C, Quiquandon I, et al: Mutations of the P53 gene in acute myeloid leukaemia. Br J Hematol 1992;80:178-183.
74. Haferlach C, Dicker F, Herholz H, et al: Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype. Leukemia 2008;22:1539-1541.
75. Cordone I, Masi S, Mauro FR, et al: p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. Blood 1998;91:4342-4349.
76. Rossi D, Cerri M, Deambrogi C, et al: The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res 2009;15:995-1004.
77. Zenz T, Eichhorst B, Busch R, et al: TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 2010;28:4473-4479.
78. Mullighan CG, Zhang J, Kasper LH, et al: CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 2011;471:235-239.
79. Goodman RH, Smolik S: CBP/p300 in cell growth, transformation, and development. Genes Dev 2000;14:1553-1577.
80. Meyer JA, Wang J, Hogan LE, et al: Relapsespecific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat Genet 2013;45:290-294.
81. Cauwelier B, Dastugue N, Cools J, et al: Molecular cytogenetic study of 126 unselected TALL cases reveals high incidence of TCRbeta locus rearrangements and putative new T-cell oncogenes. Leukemia 2006;20:1238-1244.
82. Janssen JW, Ludwig WD, Sterry W, et al: SILTAL1 deletion in T-cell acute lymphoblastic leukemia. Leukemia 1993;7:1204-1210.
83. Szczepanski T, Harrison CJ, van Dongen JJ: Genetic aberrations in paediatric acute leukaemias and implications for management of patients. Lancet Oncol 2010;11:880-889.
84. Graux C, Cools J, Melotte C, et al: Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet 2004;36:1084-1089.
85. Chiaretti S, Tavolaro S, Ghia EM, et al: Characterization of ABL1 expression in adult Tcell acute lymphoblastic leukemia by oligonucleotide arrays analysis. Haematologica 2007;92:619-626.
86. De Keersmaecker K, Graux C, Odero MD, et al: Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t (9; 14) (q34;q32). Blood 2005;105:4849-4852.
87. Ferrando AA, Neuberg DS, Staunton J, et al: Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 2002;1:75-87.
88. Ferrando AA, Armstrong SA, Neuberg DS, et al: Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood 2003;102:262-268.
89. Speleman F, Cauwelier B, Dastugue N, et al: A new recurrent inversion, inv (7) (p15q34), leads to transcriptional activation of HOXA10 and HOXA11 in a subset of T-cell acute lymphoblastic leukemias. Leukemia 2005;19:358-366.
90. Dik WA, Brahim W, Braun C, et al: CALMAF10+ T-ALL expression profiles are characterized by overexpression of HOXA and BMI1 oncogenes. Leukemia 2005;19:1948-1957.
91. Van Vlierberghe P, van Grotel M, Tchinda J, et al: The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia. Blood 2008;111:4668-4680.
92. Coustan-Smith E, Mullighan CG, Onciu M, et al: Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009;10:147-156.
93. Chiaretti S, Messina M, Tavolaro S, et al: Gene expression profiling identifies a subset of adult T-cell acute lymphoblastic leukemia with myeloid-like gene features and over-expression of miR-223. Haematologica 2010;95:1114-1121.
94. Fazi F, Rosa A, Fatica A, et al: A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis. Cell 2005;123:819-831.
95. Van Vlierberghe P, Ambesi-Impiombato A, Perez-Garcia A, et al: ETV6 mutations in early immature human T cell leukemias. J Exp Med 2011;208:2571-2579.
96. Zhang J, Ding L, Holmfeldt L, et al: The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012;481:157-163.
97. Demarest RM, Ratti F, Capobianco AJ: It's TALL about Notch. Oncogene 2008;27:5082-5091.
98. O'Neil J, Grim J, Strack P, et al: FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gammasecretase inhibitors. J Exp Med 2007;204:1813-1824.
99. Thompson BJ, Buonamici S, Sulis ML, et al: The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med 2007;204:1825-1835.
100. Asnafi V, Buzyn A, Le Noir S, et al: NOTCH1/FBXW7 mutation identifies a large subgroup with favourable outcome in adult Tcell acute lymphoblastic leukemia (TALL): a GRAALL study. Blood 2009;113:3918-3924.
101. Ben Abdelali R, Asnafi V, Leguay T, et al; Group for Research on Adult Acute Lymphoblastic Leukemia: Pediatric-inspired intensified therapy of adult T-ALL reveals the favorable outcome of NOTCH1/FBXW7 mutations, but not of low ERG/BAALC expression: a GRAALL study. Blood 2011;118:5099-5107.
102. Park MJ, Tak T, Oda M, et al: FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma. Br J Haematol 2009;145:198-206.
103. Mansour MR, Sulis ML, Duke V, et al: Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol. J Clin Oncol 2009;27:4352-4356.
104. Kox C, Zimmermann M, Stanulla M, et al: The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function. Leukemia 2010;24:2005-2013.
105. Liu P, Li P, Burke S: Critical roles of Bcl11b in T-cell development and maintenance of T-cell identity. Immunol Rev 2010;238:138-149.
106. Przybylski GK, Dik WA, Wanzeck J, et al: Disruption of the BCL11B gene through inv (14) (q11.2q32.31) results in the expression of BCL11B-TRDC fusion transcripts and is associated with the absence of wildtype BCL11B transcripts in T-ALL. Leukemia 2005;19:201-208.
107. Bernard OA, Busson-LeConiat M, Ballerini P, et al: A new recurrent and specific cryptic translocation, t (5; 14) (q35;q32), is associated with expression of the Hox11L2 gene in T acute lymphoblastic leukemia. Leukemia 2001;15:1495-1504.
108. De Keersmaecker K, Real PJ, Gatta GD, et al: The TLX1 oncogene drives aneuploidy in T cell transformation. Nat Med 2010;16:1321-1327.
109. Gutierrez A, Kentsis A, Sanda T, et al: The BCL11B tumor suppressor is mutated across the major molecular subtypes of T-cell acute lymphoblastic leukemia. Blood 2011;118:4169-4173.
110. Kraszewska MD, Dawidowska M, Szczepański T, et al: T-cell acute lymphoblastic leukaemia: recent molecular biology findings. Br J Haematol 2012;156:303-315.
111. Flex E, Petrangeli V, Stella L, et al: Somatically acquired Jak1 mutation in adult acute lymphoblastic leukemia. J Exp Med 2008;205:751-758.
112. Jeong EG, Kim MS, Nam HK, et al: Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers. Clin Cancer Res 2008;14:3716-3721.
113. Asnafi V, Le Noir S, Lhermitte L, et al: JAK1 mutations are not frequent events in adult T-ALL: a GRAALL study. Br J Haematol 2010;148:178-179.
114. Kleppe M, Lahortiga I, El Chaar T, et al: Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. Nat Genet 2010;42:530-535.
115. Kleppe M, Soulier J, Asnafi V, et al: PTPN2 negatively regulates oncogenic JAK1 in Tcell acute lymphoblastic leukemia. Blood 2011;117:7090-7098.
116. Peschon JJ, Morrissey PJ, Grabstein KH, et al: Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J Exp Med 1994;180:1955-1960.
117. Puel A, Ziegler SF, Buckley RH, et al: Defective IL7R expression in T (.) B (+) NK (+) severe combined immunodeficiency. Nat Genet 1998;20:394-397.
118. Shochat C, Tal N, Bandapalli OR, et al: Gainoffunction mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias. J Exp Med 2011;208:1333.
119. Zenatti PP, Ribeiro D, Li W, et al: Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat Genet 2011;43:932-939.
120. Van Vlierberghe P, Palomero T, Khiabanian H, et al: PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat Genet 2010;42:338-342.
121. Lower KM, Turner G, Kerr BA, et al: Mutations in PHF6 are associated with Borjeson-Forssman-Lehmann syndrome. Nat Genet 2002;32:661-665.
122. Wang Q, Qiu H, Jiang H, et al: Mutations of PHF6 are associated with mutations of NOTCH1, JAK1 and rearrangement of SETNUP214 in T-cell acute lymphoblastic leukemia. Haematologica 2011;96:1808-1814.
123. Porcu M, Kleppe M, Gianfelici V, et al: Mutation of the receptor tyrosine phosphatase PTPRC (CD45) in T-cell acute lymphoblastic leukemia. Blood 2012;119:4476-4479.
124. De Keersmaecker K, Atak ZK, Li N, et al: Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. Nat Genet 2013;45:186-190.
125. Tzoneva G, Perez-Garcia A, Carpenter Z, et al: Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nat Med 2013;19:368-371.
126. Mirandola L, Comi P, Cobos E, et al: Notching from T-cell to B-cell lymphoid malignancies. Cancer Lett 2011;308:1-13.
127. Gordon WR, Roy M, Vardar-Ulu D, et al: Structure of the Notch1-negative regulatory region: implications for normal activation and pathogenic signaling in T-ALL. Blood 2009;113:4381-4390.
128. Kelly DF, Lake RJ, Middelkoop TC, et al: Molecular structure and dimeric organization of the Notch extracellular domain as revealed by electron microscopy. PLoS One 2010;5:e10532.
129. Artavanis-Tsakonas S, Rand MD, Lake RJ: Notch signaling: cell fate control and signal integration in development. Science 1999;284:770-776.
130. Lai EC: Notch signaling: control of cell communication and cell fate. Development 2004;131:965-973.
131. Maerki S, Ceredig R, Rolink A: Induction of chemokine receptor expression during early stages of T cell development. Immunol Lett 2006;104:110-117.
132. Buonamici S, Trimarchi T, Ruocco MG, et al: CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Nature 2009;459:1000-1004.
133. Garcia-Peydro M, de Yebenes VG, Toribio ML: Notch1 and IL-7 receptor interplay maintains proliferation of human thymic progenitors while suppressing non-T cell fates. J Immunol 2006;177:3711-3720.
134. Ellisen LW, Bird J, West DC, et al: TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991;66:649-661.
135. Pear WS, Aster JC, Scott ML, et al: Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J Exp Med 1996;183:2283-2291.
136. Weng AP, Ferrando AA, Lee W, et al: Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004;306:269-271.
137. Breit S, Stanulla M, Flohr T, et al: Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood 2006;108:1151-1157.
138. Selkoe D, Kopan R: Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration. Annu Rev Neurosci 2003;26:565-597.
139. De Keersmaecker K, Lahortiga I, Mentens N, et al: In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia. Haematologica 2008;93:533-542.
140. Palomero T, Lim WK, Odom DT, et al: NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci USA 2006;103:18261-18266.
141. Palomero T, Sulis ML, Cortina M, et al: Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med 2007;13:1203-1210.
142. Real PJ, Tosello V, Palomero T, et al: Gammasecretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med 2009;15:50-58.
143. Kumar CC: Genetic abnormalities and challenges in the treatment of acute myeloid leukemia. Genes Cancer 2011;2:95-107.
144. Thomas X: Chemotherapy of acute leukemias in adults. Exp Opin Pharmacother 2009;10:221-237.
145. Farag SS, Ruppert AS, Mrozek K, et al: Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol 2005;23:482-483.
146. Klepin HD, Balducci L: Acute myelogenous leukemia in older adults. Oncologist 2009;14:222-232.
147. Vardiman JW, Thiele J, Arber DA, et al: The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937-951.
148. Martens J H A, Stunnenberg HG: The molecular signature of oncofusion proteins in acute myeloid leukemia. FEBS Lett 2010;584:2662-2669.
149. Byrd JC, Mrozek K, Dodge RK, et al; Cancer and Leukemia Group B (CALGB 8461): Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;100:4325-4336.
150. de The H, Chomienne C, Lanotte M, et al: The t (15; 17) translocation of acute promyelocytic leukemia fuses the retinoic acid receptor α gene to a novel transcribed locus. Nature 1990;347:358-361.
151. Mrozek K, Radmacher MD, Bloomfield CD, et al: Molecular signatures in acute myeloid leukemia. Curr Opin Hematol 2009;16:64-69.
152. Tallman MS, Andersen JW, Schiffer CA, et al: All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997:337:1639-1646.
153. Avvisati G, Lo Coco F, Diverio D, et al: AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood 1996;88:1390-1398.
154. Testi AM, Biondi A, Lo Coco F, et al: GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood 2005;106:447-453.
155. Avvisati G, Lo-Coco F, Paoloni FP, et al; GIMEMA, AIEOP, and EORTC Cooperative Groups: AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood 2011;117:4716-4725.
156. Licht JD: Reconstructing a disease: what essential features of the retinoic acid receptor fusion oncoproteins generate acute promyelocytic leukemia? Cancer Cell 2006;9:73-74.
157. Lo-Coco F, Avvisati G, Vignetti M, et al: Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 2013;369:111-121.
158. Davis JN, McGhee L, Meyers S: The ETO (MTG8) gene family. Gene 2003;303:1-10.
159. Kolitz JE, George SL, Dodge RK, et al; Cancer and Leukemia Group B: Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B study 9621. J Clin Oncol 2004;22:4290-4301.
160. Lutterbach B, Hiebert SW: Role of the transcription factor AML-1 in acute leukemia and hematopoietic differentiation. Gene 2000;245:223-235.
161. Eguchi M, Eguchi-Ishimae M, Greaves M: Molecular pathogenesis of MLL-associated leukemias. Int J Hematol 2005;82:9-20.
162. Parkin B, Erba H, Ouillette P, et al: Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia. Blood 2010;116:4958-4967.
163. Frohling S, Scholl C, Gilliland DG, et al: Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol 2005;23:6285-6295.
164. Schlenk RF, Dohner K, Krauter J, et al; German-Austrian Acute Myeloid Leukemia Study Group: Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008;358:1909-1918.
165. Marcucci G, Haferlach T, Dohner H: Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol 2011;29:475-486.
166. Koschmieder S, Halmos B, Levantini E, et al: Dysregulation of the C/EBPalpha differentiation pathway in human cancer. J Clin Oncol 2009;27:619-628.
167. Wouters BJ, Lowenberg B, Erpelinck-Verschueren CA, et al: Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 2009;113:3088-3091.
168. Falini B, Nicoletti I, Martelli MF, et al: Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc + AML): biologic and clinical features. Blood 2007;109:874-885.
169. Falini B, Mecucci C, Tiacci E, et al; GIMEMA Acute Leukemia Working Party: Cytoplasmic nucleophosmin in acute myelogenous leukemi with a normal karyotype. N Engl J Med 2005;352:254-266.
170. Schnittger S, Schoch C, Kern W, et al: Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005;106:3733-3739.
171. Döhner K, Döhner H: Molecular characterization of acute myeloid leukemia. Haematologica 2008;93:976-982.
172. Mrózek K, Marcucci G, Paschka P, et al: Clinical relevance of mutations and geneexpression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 2007;109:431-448.
173. Marcucci G, Maharry K, Wu YZ, et al: IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol 2010;28:2348-2355.
174. Döhner H, Estey EH, Amadori S, et al; European LeukemiaNet: Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453-474.
175. Verhaak RG, Goudswaard CS, van Putten W, et al: Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 2005;106:3747-3754.
176. Mullighan CG, Kennedy A, Zhou X, et al: Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias. Leukemia 2007;21:2000-2009.
177. Garzon R, Garofalo M, Martelli MP, et al: Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci USA 2008;105:3945-3950.
178. Dombret H: Gene mutation and AML pathogenesis. Blood 2011;118:5366-5367.
179. Mardis ER, Ding L, Dooling DJ, et al: Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009;361:1058-1066.
180. Sanson M, Marie Y, Paris S, et al: Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009;27:4150-4154.
181. Yan H, Parsons DW, Jin G, et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765-773.
182. Paschka P, Schlenk RF, Gaidzik VI, et al: IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010;28:3636-3643.
183. Andersson AK, Miller DW, Lynch JA, et al: IDH1 and IDH2 mutations in pediatric acute leukemia. Leukemia 2011;25:1570-1577.
184. Wagner K, Damm F, Göhring G, et al: Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol 2010;28:2356-2364.
185. Figueroa ME, Abdel-Wahab O, Lu C, et al: Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010;18:553-567.
186. Ley TJ, Ding L, Walter MJ, et al: DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010;363:2424-2433.
187. Thol F, Damm F, Lüdeking A, et al: Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol 2011;29:2889-2896.
188. Thol F, Heuser M, Damm F, et al: DNMT3A mutations are rare in childhood acute myeloid leukemia. Haematologica 2011;96:1238-1240.
189. Paganin M, Pigazzi M, Bresolin S, et al: A methyltransferase 3a hot-spot locus is not mutated in pediatric patients affected by acute myeloid or T-cell acute lymphoblastic leukemia: an Italian study. Haematologica 2011;96:1886-1887.
190. Grossmann V, Tiacci E, Holmes AB, et al: Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. Blood 2011;118:6153-6163.
191. Ng D, Thakker N, Corcoran CM, et al: Oculofaciocardiodental and Lenz microphthalmia syndromes result from distinct classes of mutations in BCOR. Nat Genet 2004;36:411-416.
192. Delhommeau F, Dupont S, Della Valle V, et al: Mutation in TET2 in myeloid cancers. N Engl J Med 2009;360:2289-2301.
193. Abdel-Wahab O, Mullally A, Hedvat C, et al: Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009;114:144-147.
194. Tefferi A, Pardanani A, Lim KH, et al: TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009;23:905-911.
195. Kosmider O, Gelsi-Boyer V, Ciudad M, et al; Groupe Francophone des Myélodysplasies: TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica 2009;94:1676-1681.
196. Welch JS, Ley TJ, Link DC, et al: The origin and evolution of mutations in acute myeloid leukemia. Cell 2012;150:264-278.
197. Cancer Genome Atlas Research Network: Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013;368:2059-2074.
198. Schoch C, Kohlmann A, Schnittger S, et al: Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles. Proc Natl Acad Sci USA 2002;99:10008-10013.
199. Bullinger L, Döhner K, Bair E, et al: Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 2004;350:1605-1616.
200. Valk PJ, Verhaak RG, Beijen MA, et al: Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004;350:1617-1628.
201. Schoch C, Kern W, Kohlmann A, et al: Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile. Genes Chromosomes Cancer 2005;43:227-238.
202. Rücker FG, Bullinger L, Schwaenen C, et al: Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization. J Clin Oncol 2006;24:3887-3894.
203. Marcucci G, Maharry K, Radmacher MD: Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with highrisk molecular features: a Cancer and Leukemia Group B Study. J Clin Oncol 2008;26:5078-5087.
204. Wouters BJ, Jordà MA, Keeshan K, et al: Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. Blood 2007;110:3706-3714.
205. Neben K, Schnittger S, Brors B: Distinct gene expression patterns associated with FLT3- and NRAS-activating mutations in acute myeloid leukemia with normal karyotype. Oncogene 2005;24:1580-1588.
206. Langer C, Radmacher MD, Ruppert AS, et al; Cancer and Leukemia Group B (CALGB): High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. Blood 2008;111:5371-5379.
207. Langer C, Marcucci G, Holland KB, et al: Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol 2009;27:3198-3204.
208. Radmacher MD, Marcucci G, Ruppert AS, et al; Cancer and Leukemia Group B: Independent confirmation of a prognostic gene expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study. Blood 2006;108:1677-1683.
209. Mi S, Lu J, Sun M, et al: RNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci USA 2007;104:19971-19976.
210. Mi S, Li Z, Chen P, et al: Aberrant overexpression and function of the miR-17-92 cluster in MLL-rearranged acute leukemia. Proc Natl Acad Sci USA 2010;107:3710-3715.
211. Li Z, Lu J, Sun M, et al: Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci USA 2008;105:15535-15540.
212. Dixon-McIver A, East P, Mein CA, et al: Distinctive patterns of microRNA expression associated with karyotype in acute myeloid leukaemia. PLoS One 2008;14;3:e2141.
213. O'Connell RM, Chaudhuri AA, Rao DS, et al: Inositol phosphatase SHIP1 is a primary target of miR-155. Proc Natl Acad Sci USA 2009;106:7113-7118.
214. Garzon R, Volinia S, Liu CG, et al.: Micro-RNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 2008;111:3183-3189.
215. Marcucci G, Radmacher MD, Maharry K, et al.: MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008;358:1919-1928.